Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced ...
Model output · Signal date 2026-10-14
Entera Bio Ltd. (ENTX) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 4004 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$431M
small-cap · #60 of 60 peers
Summary
Entera Bio Ltd. (ENTX) stock forecast summary
Our AI ranks Entera Bio Ltd. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Entera Bio Ltd. is a small-cap company with a market capitalization of $431M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for ENTX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ENTX included.
Follow ENTX freePrice
ENTX price chart and AI forecast
Cross-section · 2026-10-14
How ENTX ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Entera Bio Ltd. (ENTX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | ENTX | Rank |
|---|---|---|
| Market Cap | $431M | 60/60 |
| P/B Ratio | 59.33x | 4/50 |
| EPS | $0.33 | – |
| Book Value/Share | $0.04 | – |
| Revenue/Share | $0.00 | – |
| FCF/Share | $-0.06 | – |
Profitability & Margins
| Metric | ENTX | Rank |
|---|---|---|
| ROIC | -82.9% | 43/50 |
Financial Health
| Metric | ENTX | Rank |
|---|---|---|
| Current Ratio | 8.98x | 18/54 |
| D/E Ratio | 1.68x | 8/50 |
| Financial Leverage | 2.68x | 8/50 |
| Working Capital | $17M | 53/54 |
Cash Flow
| Metric | ENTX | Rank |
|---|---|---|
| Operating Cash Flow | -$11M | 16/52 |
| Free Cash Flow | -$11M | 15/45 |
| Capital Spending | -$70K | 2/45 |
Operational Efficiency
| Metric | ENTX | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 32/34 |
| Fixed Assets Turnover | 0.0x | 33/34 |
Income Statement
| Metric | ENTX | Rank |
|---|---|---|
| Total Revenue | $0.00M | 33/34 |
| Operating Income | -$14M | 13/50 |
| R&D Expense | $9M | 50/51 |
| SG&A Expense | $550K | 22/22 |
| Cost of Goods Sold | $0.00M | 23/23 |
Dividend & Shareholder Information
| Metric | ENTX | Rank |
|---|---|---|
| Shares Outstanding | 173M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $19M | 97.0% of assets |
| Cash & Short-term Investments | $11M | 58.1% of assets |
| Total Liabilities | $12M | 62.7% of assets |
| Short-term Debt | $2M | 7.9% of assets |
Quarterly Financial Reports
ENTX quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Entera Bio Ltd. (ENTX) industry peers
Companies classified under the same SEC industry code as Entera Bio Ltd. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ENTX Entera Bio Ltd. | ▲ | $431M |
| AMGN Amgen Inc | ▼ | $223.19B |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B |
| MRNA Moderna, Inc. | ▲ | $86.33B |
| ARGX Argenx Se | ▶ | $49.67B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.39B |
| BIIB Biogen Inc. | ▼ | $33.79B |
| BNTX Biontech Se | ▶ | $22.51B |
| MESO Mesoblast Ltd | ▼ | $18.02B |
| EXEL Exelixis, Inc. | ▲ | $14.75B |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.44B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.39B |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B |
| RGEN Repligen Corp | ▲ | $9.90B |
| QGEN Qiagen N.V. | ▼ | $9.86B |
| KRYS Krystal Biotech, Inc. | ▲ | $9.51B |
| TWST Twist Bioscience Corp | ▲ | $9.49B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B |
| IMVT Immunovant, Inc. | ▲ | $5.93B |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.53B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.93B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.80B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.11B |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.05B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B |
| ALVO Alvotech | ▶ | $1.68B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B |
| IMCR Immunocore Holdings Plc | ▲ | $1.43B |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.17B |
| REPL Replimune Group, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.13B |
| JATT Zura Bio Ltd | ▼ | $1000M |
| VALN Valneva Se | ▼ | $965M |
| MGTX Meiragtx Holdings Plc | ▶ | $955M |
| IMTX Immatics N.V. | ▶ | $916M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M |
| SANA Sana Biotechnology, Inc. | ▶ | $721M |
| CADL Candel Therapeutics, Inc. | ▲ | $709M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M |
| AURA Aura Biosciences, Inc. | ▲ | $650M |
| SLDB Solid Biosciences Inc. | ▲ | $624M |
| PRME Prime Medicine, Inc. | ▲ | $602M |
Where ENTX sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Entera Bio Ltd. (ENTX) stock news
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fr…
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women ...
Entera Bio Strengthens Board with Veteran Biopharma Leader
An update from Entera Bio ( ) is now available. On October 6, 2026, Entera Bio announced the appointment of veteran biopharmaceutical executive Laura Hamill as a Class I director, ...
FAQ
Entera Bio Ltd. (ENTX) stock forecast FAQ
What is the Entera Bio Ltd. (ENTX) stock forecast?
Our AI ranks Entera Bio Ltd. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Entera Bio Ltd. stock predictions?
A per-ticker accuracy statistic for ENTX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Entera Bio Ltd. forecasts updated?
Entera Bio Ltd. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Entera Bio Ltd.'s industry peers?
60 issuers in our coverage, ENTX included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.